
Development of a Targeted Radiotherapeuitc for Pancreatic Ductal AdenocarcinomaAward last edited on: 1/24/2022
Sponsored Program
STTRAwarding Agency
NIH : NCITotal Award Amount
$400,000Award Phase
1Solicitation Topic Code
395Principal Investigator
Jered C GarrisonCompany Information
AdductNE LLC
1604 North 154th Street
Omaha, NE 68154
Omaha, NE 68154
(402) 637-1002 |
N/A |
N/A |
Research Institution
----------
Phase I
Contract Number: 1R41CA254492-01A1Start Date: 9/21/2021 Completed: 8/31/2022
Phase I year
2021Phase I Amount
$400,000Project Terms:
Biopsy ; Blood ; Blood Reticuloendothelial System ; Clinical Trials ; Consultations ; Cessation of life ; Death ; Diagnosis ; Disease ; Disorder ; Pharmaceutical Preparations ; Drugs ; Medication ; Pharmaceutic Preparations ; drug/agent ; Investigational Drugs ; Investigational New Drugs ; Goals ; Grant ; Human ; Modern Man ; In Vitro ; Kidney ; Kidney Urinary System ; renal ; Laboratories ; Licensure ; Molecular Weight ; Nebraska ; Patients ; Peptide Hydrolases ; Esteroproteases ; Peptidases ; Protease Gene ; Proteases ; Proteinases ; Proteolytic Enzymes ; Radiation therapy ; Radiotherapeutics ; Radiotherapy ; radiation treatment ; radio-therapy ; treatment with radiation ; Risk ; Safety ; Survival Rate ; Technology ; Time ; Treatment Protocols ; Treatment Regimen ; Treatment Schedule ; Universities ; Neurotensin Receptors ; Measures ; New Drug Approvals ; Label ; Radiopharmaceuticals ; Radiopharmaceutical Compound ; radioactive drugs ; radiotherapeutic drugs ; improved ; Radionuclide therapy ; therapeutic radionuclide ; Clinical ; Phase ; residence ; residential building ; residential site ; uptake ; Radiosensitization ; chemo-/radio-sensitization ; radio-/chemo-sensitization ; radio-sensitization ; radio-sensitizes ; radiosensitizing ; Radiation Toxicity ; Acute Radiation Syndrome ; Radiotoxicity ; radiation poisoning ; Therapeutic ; Normal Tissue ; Normal tissue morphology ; Malignant Pancreatic Neoplasm ; Pancreas Cancer ; Pancreatic Cancer ; pancreatic malignancy ; Malignant neoplasm of pancreas ; Clinic ; Tumor Volume ; Tumor Tissue ; Operative Procedures ; Surgical ; Surgical Interventions ; Surgical Procedure ; surgery ; Operative Surgical Procedures ; residual disease ; Residual Tumors ; Radiation Dose ; Radiation Dose Unit ; Medical center ; adduct ; Receptor Protein ; receptor ; Animal Models and Related Studies ; model of animal ; model organism ; Animal Model ; dosimetry ; Toxicities ; Toxic effect ; Structure ; novel ; Maximal Tolerated Dose ; Maximally Tolerated Dose ; Maximum Tolerated Dose ; Cancer Treatment ; Malignant Neoplasm Therapy ; Malignant Neoplasm Treatment ; anti-cancer therapy ; anticancer therapy ; cancer-directed therapy ; cancer therapy ; cancer diagnosis ; Pharmaceutical Agent ; Pharmaceuticals ; Pharmacological Substance ; Pharmacologic Substance ; Pancreas Ductal Adenocarcinoma ; Pancreatic Ductal Adenocarcinoma ; Dose ; Affinity ; Dose-Limiting ; in vivo ; Cancer Etiology ; Cancer Cause ; External Beam Radiation Therapy ; Definitive Radiation Therapy ; EBRT ; External Beam RT ; External Radiation ; external-beam radiation ; Patient-Focused Outcomes ; Patient outcome ; Patient-Centered Outcomes ; Small Business Technology Transfer Research ; STTR ; Xenograft Model ; xenograft transplant model ; xenotransplant model ; Monitor ; Development ; developmental ; Pathway interactions ; pathway ; Treatment Efficacy ; intervention efficacy ; therapeutic efficacy ; therapy efficacy ; Outcome ; scale up ; chemotherapy ; novel therapeutics ; new drug treatments ; new drugs ; new therapeutics ; new therapy ; next generation therapeutics ; novel drug treatments ; novel drugs ; novel therapy ; mouse model ; murine model ; commercial application ; commercialization ; tumor ; overexpression ; overexpress ; manufacturing scale-up ; comparative efficacy ; compare efficacy ; Regimen ; targeted agent ; clinical translation ; first-in-human ; first in man ; targeted radiotherapeutic ; pancreatic ductal adenocarcinoma model ; PDA model ; PDAC Model ; Prognosis ;
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00